


**AMENDMENTS TO THE CLAIMS**

Please amend the claims as follows:

1. (Currently amended) ~~Compounds~~ A compound of the general formula 1:



**General Formula 1**

wherein:

Py represents pyridin-4-yl mono-substituted in position 2 with  $-NR^2R^3$ ; pyridin-4-yl disubstituted in position 2 with  $-NR^2R^3$  and in position 6 with lower alkyl or arylalkyl; unsubstituted quinolin-4-yl; quinolin-4-yl mono-substituted in position 2 with lower alkyl; quinolin-4-yl di-substituted in position 2 with lower alkyl and in position 6, 7, or 8 with halogen, lower alkyl, or arylalkyl; 2-hydroxymethyl-quinolin-4-yl; 7-methyl-[1,8]naphthyridin-4-yl; 5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-benzyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-methyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; 1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; 1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl;

X represents aryl; aryl-O-; arylalkyl-; lower alkyl-SO<sub>2</sub>NR<sup>2</sup>-; aryl-SO<sub>2</sub>NR<sup>2</sup>-; arylalkyl-SO<sub>2</sub>NR<sup>2</sup>-; lower alkyl-CONR<sup>2</sup>-; aryl-CONR<sup>2</sup>-; arylalkyl-CONR<sup>2</sup>-; lower alkyl-NR<sup>3</sup>CONR<sup>2</sup>-; aryl-NR<sup>3</sup>CONR<sup>2</sup>-; arylalkyl-NR<sup>3</sup>CONR<sup>2</sup>-; aryl-CO-; arylalkyl-CO-; lower alkyl-NR<sup>2</sup>CO-; aryl-NR<sup>2</sup>CO-; arylalkyl-NR<sup>2</sup>CO-; or X and Z represent together with the carbon atom to which they are attached an exocyclic double bond which bears an aryl substituent.

Y represents  $-C(R^4)(R^5)(CH_2)_m-$  or  $-(CH_2)_mC(R^4)(R^5)-$

Z represents hydrogen; in case X represents aryl or arylalkyl, Z represents hydrogen, hydroxyl, carboxyl, aryl-CONR<sup>2</sup>-, lower alkyl-NR<sup>2</sup>CO-, aryl-NR<sup>2</sup>CO- or arylalkyl-NR<sup>2</sup>CO-;

n represents the numbers 0 or 1;

m represents the numbers 1 or 2;

R<sup>1</sup> represents hydrogen or lower alkyl;


R<sup>2</sup> and R<sup>3</sup> represent independently hydrogen, lower alkyl, or arylalkyl; in case R<sup>2</sup> and R<sup>3</sup> are attached to the same nitrogen atom, R<sup>2</sup> and R<sup>3</sup> together form with the nitrogen to which they are attached, a piperidine, pyrrolidine or morpholine ring;

R<sup>4</sup> represents hydrogen, lower alkyl, aryl, arylalkyl, or forms together with R<sup>5</sup> a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R<sup>4</sup> and R<sup>5</sup> are attached as ring atoms;

R<sup>5</sup> represents hydrogen, methyl, or forms together with R<sup>4</sup> a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R<sup>4</sup> and R<sup>5</sup> are attached as ring atoms;

and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, and mixtures of diastereomeric racemates; as well as their pharmaceutically acceptable salts, solvent complexes, and morphological forms.

2. (Currently amended) ~~Compounds~~ A compound of the general formula 2,



**General Formula 2**

wherein:

Py represents 2-(benzyl-methyl-amino)-pyridin-4-yl; 2-(benzyl-methyl-amino)-6-methyl-pyridin-4-yl; 2-(benzylamino)-pyridin-4-yl; 2-benzylamino-6-methyl-pyridin-4-yl; 2-(dimethylamino)-pyridin-4-yl; 2-(dimethylamino)-6-methyl-pyridin-4-yl; 2-(methylamino)-pyridin-4-yl; 2-(methylamino)-6-methyl-pyridin-4-yl; 2-aminopyridin-4-yl; 2-amino-6-methyl-pyridin-4-yl; 2-(pyrrolidin-1-yl)-pyridin-4-yl; quinol-4-yl; 2-methylquinol-4-yl; 2-cyclopropylquinol-4-yl; 8-benzyl-2-methyl-quinol-4-yl; [1,8]naphthyridin-4-yl; 7-methyl-[1,8]naphthyridin-4-yl; 5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-benzyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-methyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; 1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; 1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl;

X represents aryl; aryl-O-; arylalkyl-; lower alkyl-SO<sub>2</sub>NR<sup>2</sup>-; aryl-SO<sub>2</sub>NR<sup>2</sup>-; arylalkyl-SO<sub>2</sub>NR<sup>2</sup>-; lower alkyl-CONR<sup>2</sup>-; aryl-CONR<sup>2</sup>-; arylalkyl-CONR<sup>2</sup>-; lower alkyl-NR<sup>3</sup>CONR<sup>2</sup>-; aryl-NR<sup>3</sup>CONR<sup>2</sup>-; arylalkyl-NR<sup>3</sup>CONR<sup>2</sup>-; aryl-CO-; arylalkyl-CO-; lower alkyl-NR<sup>2</sup>CO-; aryl-NR<sup>2</sup>CO-; arylalkyl-NR<sup>2</sup>CO-;

Z represents hydrogen; in case X represents aryl or arylalkyl, Z represents hydrogen or hydroxyl;


n represents the numbers 0 or 1;

m represents the numbers 1 or 2;

R<sup>1</sup> represents hydrogen or lower alkyl;


R<sup>2</sup> and R<sup>3</sup> represent independently hydrogen, lower alkyl, or arylalkyl;

3. (Currently amended) ~~Compounds~~ A compound of general formula 3,




wherein n, Y and Py have the meaning given in general formula 1 of claim 1.

4. (Currently amended) ~~Compounds~~ A compound of general formula 4,




wherein n and Py has the meaning given in general formula 2 of claim 2.

5. (Currently amended) ~~Compounds~~ A compound of general formula 5,




wherein R<sup>2</sup>, Y and Py have the meaning given in general formula 1 of claim 1.

6. (Currently amended) ~~Compounds~~ A compound of general formula 6,




wherein R<sup>2</sup> and Py have the meaning given in general formula 2 of claim 2.

7. (Currently amended) ~~Compounds~~ A compound of general formula 7,




wherein R<sup>2</sup>, Y and Py have the meaning given in general formula 1 of claim 1.

8. (Currently amended) ~~Compounds~~ A compound of general formula 8,




wherein R<sup>2</sup>, Y and Py have the meaning given in general formula 1 of claim 1.

9. (Currently amended) ~~Compounds~~ A compound of general formula 9,




wherein R<sup>2</sup> and Py have the meaning given in general formula 2 of claim 2.

10. (Currently amended) ~~Compounds~~ A compound of general formula 10,




wherein X, Z and Py have the meaning given in general formula 1 of claim 1.

11. (Currently amended) ~~Compounds~~ A compound of general formula 11,



wherein R<sup>6</sup> is hydrogen, lower alkyl, or arylalkyl; and n, X, Y, and Z have the meaning given in general formula 1 of claim 1.


12. (Currently amended) ~~Compounds~~ A compound of general formula 12,



General formula 12

wherein  $R^6$  has the meaning given in general formula 11 of claim 11; and  $n$ ,  $X$  and  $Z$  have the meaning given in general formula 2 of claim 2.


13. (Currently amended) ~~Compounds~~ A compound of general formula 13,



General formula 13

wherein  $R^6$  has the meaning given in general formula 11 of claim 11; and  $n$ ,  $R^2$ ,  $R^3$ ,  $X$ ,  $Y$ , and  $Z$  have the meaning given in general formula 1 of claim 1.


14. (Currently amended) ~~Compounds~~ A compound of general formula 14,



General formula 14

wherein  $R^6$  has the meaning given in general formula 11 of claim 11; and  $n$ ,  $R^2$ ,  $R^3$ ,  $X$  and  $Z$  have the meaning given in general formula 1 of claim 1.


15. (Currently amended) ~~Compounds~~ A compound of general formula 15,



General formula 15

wherein R<sup>6</sup> has the meaning given in general formula 11 of claim 11.


16. (Currently amended) ~~Compounds~~ A compound of general formula 16,



General formula 16

wherein R<sup>6</sup> has the meaning given in general formula 11 of claim 11.


17. (Currently amended) ~~Compounds~~ A compound of general formula 17,



General formula 17

wherein R<sup>6</sup> has the meaning given in general formula 11 of claim 11; and R<sup>2</sup> has the meaning given in general formula 1 of claim 1.


18. (Currently amended) ~~Compounds~~ A compound of general formula 18,



General formula 18

wherein R<sup>6</sup> has the meaning given in general formula 11 of claim 11; and R<sup>2</sup> has the meaning given in general formula 1 of claim 1.


19. (Currently amended) ~~Compounds~~ A compound of general formula 19,



General formula 19

wherein R<sup>6</sup> has the meaning given in general formula 11 of claim 11; and R<sup>2</sup> has the meaning given in general formula 1 of claim 1.

20. (Currently amended) ~~Compounds~~ A compound of general formula 20,



General formula 20

wherein R<sup>6</sup> has the meaning given in general formula 11 of claim 11; and R<sup>2</sup> has the meaning given in general formula 1 of claim 1.

21. (Currently amended) The compound according to ~~any one of claims 1 to 20~~ claim 1 that is selected from the group consisting of

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-trifluoromethyl-benzenesulfonamide;

N-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

Thiophene-2-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

3-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

3,N-Dimethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;



2-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide<sub>i</sub>

2,N-Dimethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide<sub>i</sub>

4-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide<sub>i</sub>

4-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide<sub>i</sub>

4,N-Dimethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide<sub>i</sub>

2-Fluoro-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide<sub>i</sub>

2-Fluoro-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide<sub>i</sub>

3-Fluoro-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide<sub>i</sub>

4-Fluoro-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide<sub>i</sub>

4-Cyano-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide<sub>i</sub>

3-Methoxy-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide<sub>i</sub>

3-Methoxy-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide<sub>i</sub>

4-Methoxy-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

4-Methoxy-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Methoxy-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

3-Chloro-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

3-Chloro-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Chloro-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

4-Chloro-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

2-Chloro-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

Biphenyl-4-sulfonic acid methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-4-propyl-benzenesulfonamide;

N-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-4-propyl-benzenesulfonamide;

Naphthalene-2-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

Naphthalene-2-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

Naphthalene-2-sulfonic acid methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

Naphthalene-1-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

Naphthalene-1-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

Naphthalene-1-sulfonic acid methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

Quinoline-8-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

Quinoline-8-sulfonic acid methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

4-tert-Butyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-tert-Butyl-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-4-trifluoromethyl-benzenesulfonamide;

N-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-4-trifluoromethyl-benzenesulfonamide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-trifluoromethyl-benzenesulfonamide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-2-trifluoromethyl-benzenesulfonamide;

N-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-2-trifluoromethyl-benzenesulfonamide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-3-trifluoromethyl-benzenesulfonamide;

3,4-Dichloro-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

3,4-Dichloro-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-pentyl-benzenesulfonamide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-4-pentyl-benzenesulfonamide;

N-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-4-pentyl-benzenesulfonamide;

4-Butoxy-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Butoxy-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4,5-Dichloro-thiophene-2-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

4,5-Dichloro-thiophene-2-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

4,5-Dichloro-thiophene-2-sulfonic acid methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

4-(3-Chloro-2-cyano-phenoxy)-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

4-(3-Chloro-2-cyano-phenoxy)-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-(3-Chloro-2-cyano-phenoxy)-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

N-[4-Methyl-5-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)sulfamoyl]-thiazol-2-yl]-acetamide;

3-Bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

3-Bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

3-Bromo-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

4-Bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-2-trifluoromethoxy-benzenesulfonamide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-trifluoromethoxy-benzenesulfonamide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-4-trifluoromethoxy-benzenesulfonamide;

N-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-4-trifluoromethoxy-benzenesulfonamide;

5-Dimethylamino-naphthalene-1-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

5-Dimethylamino-naphthalene-1-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

5-Dimethylamino-naphthalene-1-sulfonic acid methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonic acid methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

4-Bromo-2-ethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

4-Bromo-2-ethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-2-ethyl-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

N-[5-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)sulfamoyl)-thiophen-2-ylmethyl]-benzamide;

N-[5-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)sulfamoyl)-thiophen-2-ylmethyl]-benzamide;

N-{5-[Methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-sulfamoyl]-thiophen-2-ylmethyl}-benzamide;

4-Benzenesulfonyl-thiophene-2-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

4-Benzenesulfonyl-thiophene-2-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

4-Benzenesulfonyl-thiophene-2-sulfonic acid methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

2-(2,2,2-Trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

2-(2,2,2-Trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

2-(2,2,2-Trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonic acid methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

2-Phenyl-ethanesulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

4-Chloro-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

1-{2-[4-(3-Biphenyl-2-yl-ureido)-piperidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea<sub>i</sub>

1-{2-[3-(3-Biphenyl-2-yl-ureido)-pyrrolidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea<sub>i</sub>

1-(2-{4-[3-(2-Isopropyl-phenyl)-ureido]-piperidin-1-yl}-ethyl)-3-(2-methyl-quinolin-4-yl)-urea<sub>i</sub>

1-(2-{3-[3-(2-Isopropyl-phenyl)-ureido]-pyrrolidin-1-yl}-ethyl)-3-(2-methyl-quinolin-4-yl)-urea<sub>i</sub>

1-(2-Methyl-quinolin-4-yl)-3-(2-{3-[3-(2-phenoxy-phenyl)-ureido]-pyrrolidin-1-yl}-ethyl)-urea<sub>i</sub>

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-naphthalen-1-yl-acetamide<sub>i</sub>

2-(4-Bromo-phenyl)-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-acetamide<sub>i</sub>

4-Benzoyl-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzamide<sub>i</sub>

1-(2-Methyl-quinolin-4-yl)-3-[2-(4-phenyl-piperidin-1-yl)-ethyl]-urea<sub>i</sub>

1-(2-Methyl-quinolin-4-yl)-3-[2-(4-o-tolyl-piperidin-1-yl)-ethyl]-urea<sub>i</sub>

1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea<sub>i</sub>

1-[2-(4-Hydroxy-4-phenyl-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea<sub>i</sub>

1-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea<sub>i</sub> and

1-[2-(Benzyl-methyl-amino)-pyridin-4-yl]-3-[2-(4-benzyl-piperidin-1-yl)-ethyl]-urea<sub>i</sub>



22. (Currently amended) The compound according to ~~any one of claims 1 to 20~~ claim 1 that is selected from the group consisting of

4-Bromo-N-ethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

4-Bromo-N-ethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-N-propyl-benzenesulfonamide;

4-Bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-N-propyl-benzenesulfonamide;

4-Bromo-N-isobutyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

4-Bromo-N-isobutyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-N-butyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

4-Bromo-N-butyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

N-Benzyl-4-bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

N-Benzyl-4-bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-N-phenethyl-benzenesulfonamide;

4-Bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-N-phenethyl-benzenesulfonamide;

4-Bromo-N-methyl-N-((R)-1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-N-ethyl-N-((R)-1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-N-ethyl-N-((S)-1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-N-methyl-N-((S)-1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

N-Ethyl-3-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

N-Ethyl-4-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

N-Ethyl-2-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

3-Chloro-N-ethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

2-Chloro-N-ethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

4-Chloro-N-ethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

N-Ethyl-4-fluoro-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

N-Ethyl-4-methoxy-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide<sub>i</sub>

3,4-Dichloro-N-ethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide<sub>i</sub>

N-Ethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-trifluoromethyl-benzenesulfonamide<sub>i</sub>

1-(2-Methyl-quinolin-4-yl)-3-{2-[4-(3-phenethyl-ureido)-piperidin-1-yl]-ethyl}-urea<sub>i</sub>

1-[(S)-1-(4-Benzyl-piperidin-1-yl)methyl)-2-methyl-propyl]-3-(2-methyl-quinolin-4-yl)-urea<sub>i</sub>

1-[(S)-1-Benzyl-2-(4-benzyl-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea<sub>i</sub>

1-[(S)-1-(4-Benzyl-piperidin-1-yl)methyl)-3-methyl-butyl]-3-(2-methyl-quinolin-4-yl)-urea<sub>i</sub>

1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-cyclopropyl-quinolin-4-yl)-urea<sub>i</sub>

1-{2-[4-(3-Methyl-benzylidene)-piperidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea<sub>i</sub>

1-{2-[4-(2-Methyl-benzylidene)-piperidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea<sub>i</sub>

1-{2-[4-(4-Methoxy-benzylidene)-piperidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea<sub>i</sub>

1-{2-[4-(4-Fluoro-benzylidene)-piperidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea<sub>i</sub>

1-{2-[4-(4-Bromo-benzylidene)-piperidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea<sub>i</sub>

1-{2-[4-(3-Methyl-benzyl)-piperidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea;

1-{2-[4-(2-Methyl-benzyl)-piperidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea;

1-{2-[4-(4-Fluoro-benzyl)-piperidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea;

1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-piperidine-4-carboxylic acid benzyl-phenyl-amide;

1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-piperidine-4-carboxylic acid (2-chloro-phenyl)-methyl-amide;

1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid benzyl-methyl-amide;

1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid methyl-phenethyl-amide;

1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid benzyl-ethyl-amide;

1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid dimethylamide;

4-Benzyl-1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidine-4-carboxylic acid benzyl-ethyl-amide;

1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methylamino-pyridin-4-yl)-urea; and

1-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-3-(2-methylamino-pyridin-4-yl)-urea;

23. (Currently amended) ~~Pharmaceutical compositions containing a~~ A  
pharmaceutical composition comprising the compound of any one of claims 1 to  
22, and usual carrier materials a pharmaceutically acceptable carrier and  
optionally adjuvants an adjuvant for the treatment of disorders which are

~~associated with a dysregulation of urotensin II or urotensin II receptors, or disorders associated with vascular or myocardial dysfunction, comprising hypertension, atherosclerosis, angina or myocardial ischemia, congestive heart failure, cardiac insufficiency, cardiac arrhythmias, renal ischemia, chronic kidney disease, renal failure, stroke, cerebral vasospasm, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, diabetes, diabetic arteriopathy, diabetic nephropathy, connective tissue diseases, cirrhosis, asthma, chronic obstructive pulmonary disease, high-altitude pulmonary edema, Raynaud's syndrome, portal hypertension, thyroid dysfunction, pulmonary edema, pulmonary hypertension, or pulmonary fibrosis.~~

24. (Cancelled).

25. (Cancelled).

26. (Cancelled).

27. (Currently amended) ~~The A method of treating a patient suffering from a disorder given in any one of claims 23 to 26 by~~ selected from the group consisting of hypertension, atherosclerosis, angina or myocardial ischemia, congestive heart failure, cardiac insufficiency, cardiac arrhythmias, renal ischemia, chronic kidney disease, renal failure, stroke, cerebral vasospasm, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, diabetes, diabetic arteriopathy, diabetic nephropathy, connective tissue diseases, cirrhosis, asthma, chronic obstructive pulmonary disease, high-altitude pulmonary edema, Raynaud's syndrome, portal hypertension, thyroid dysfunction, pulmonary edema, pulmonary hypertension, pulmonary fibrosis, restenosis after balloon or stent angioplasty, cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, sickle cell acute chest syndrome, glomerulonephritis, renal colic, glaucoma, therapy and prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, pain, addiction, schizophrenia, Alzheimer's disease, anxiety, obsessive-

compulsive behavior, epileptic seizures, stress, depression, dementias, neuromuscular disorders, and neurodegenerative diseases, comprising administering a the pharmaceutical composition according to any one of claims 23 and 24 of claim 23.

28. (New) The pharmaceutical composition of claim 23 further comprising a pharmacologically active compound selected from the group consisting of ACE inhibitors, angiotensin II receptor antagonists, endothelin receptor antagonists, vasopressin antagonists, beta-adrenergic antagonists, alpha-adrenergic antagonists, vasopressin antagonists, TNFalpha antagonists, and peroxisome proliferator activator receptor modulators.
29. (New) A method of treating a patient suffering from a disorder selected from the group consisting of hypertension, atherosclerosis, angina or myocardial ischemia, congestive heart failure, cardiac insufficiency, cardiac arrhythmias, renal ischemia, chronic kidney disease, renal failure, stroke, cerebral vasospasm, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, diabetes, diabetic arteriopathy, diabetic nephropathy, connective tissue diseases, cirrhosis, asthma, chronic obstructive pulmonary disease, high-altitude pulmonary edema, Raynaud's syndrome, portal hypertension, thyroid dysfunction, pulmonary edema, pulmonary hypertension, pulmonary fibrosis, restenosis after balloon or stent angioplasty, cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, sickle cell acute chest syndrome, glomerulonephritis, renal colic, glaucoma, therapy and prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, pain, addiction, schizophrenia, Alzheimer's disease, anxiety, obsessive-compulsive behavior, epileptic seizures, stress, depression, dementias, neuromuscular disorders, and neurodegenerative diseases, comprising administering the pharmaceutical composition of claim 28.